182 related articles for article (PubMed ID: 38745179)
1. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract][Full Text] [Related]
2. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
Li Q; Yuan H; Zhao G; Ou D; Zhang J; Li L; Li S; Feng T; Gu R; Kou Q; Wang Q; Li S; Wang G; Zhao M; Yu H; Qu J; Lin P; Li K
Biochem Pharmacol; 2024 Jul; 225():116251. PubMed ID: 38701867
[TBL] [Abstract][Full Text] [Related]
3. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
4. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
5. CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis.
Xu Q; Zhou L; Yang G; Meng F; Wan Y; Wang L; Zhang L
Cell Biol Int; 2020 Nov; 44(11):2344-2356. PubMed ID: 32808701
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
8. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Elkateb AS; Nofal S; Ali SA; Atya HB
Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
[TBL] [Abstract][Full Text] [Related]
10. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
Li X; Li Y; Lian P; Lv Q; Liu F
Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
[TBL] [Abstract][Full Text] [Related]
11. APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy.
Du Y; Zhou Y; Yan X; Pan F; He L; Guo Z; Hu Z
Cell Death Differ; 2024 Apr; 31(4):431-446. PubMed ID: 38418695
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.
Yao F; Zhou S; Zhang R; Chen Y; Huang W; Yu K; Yang N; Qian X; Tie X; Xu J; Zhang Y; Baheti T; Xu J; Dai X; Hao X; Zhang L; Wang X; Li Q
Cancer Lett; 2024 Jul; 593():216935. PubMed ID: 38704136
[TBL] [Abstract][Full Text] [Related]
13. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
14. Ketamine Induces Ferroptosis of Liver Cancer Cells by Targeting lncRNA PVT1/miR-214-3p/GPX4.
He GN; Bao NR; Wang S; Xi M; Zhang TH; Chen FS
Drug Des Devel Ther; 2021; 15():3965-3978. PubMed ID: 34566408
[TBL] [Abstract][Full Text] [Related]
15. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.
Liu Y; Shao K; Yang W; Shen Q; Lu M; Shao Z; Chu S; Wang Y; Wang X; Chen X; Bai J; Wu X
Cell Death Dis; 2024 Jun; 15(6):395. PubMed ID: 38839744
[TBL] [Abstract][Full Text] [Related]
18. GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis.
Pan R; Zhao Z; Xu D; Li C; Xia Q
Transl Res; 2024 Sep; 271():79-92. PubMed ID: 38797432
[TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation.
Gao Y; Tong M; Wong TL; Ng KY; Xie YN; Wang Z; Yu H; Loh JJ; Li M; Ma S
ACS Nano; 2023 Nov; 17(22):22240-22258. PubMed ID: 37966480
[TBL] [Abstract][Full Text] [Related]
20. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
